MedPath

Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate

Phase 1
Completed
Conditions
Healthy
Interventions
Dietary Supplement: HMB Free Acid Gel
Dietary Supplement: CaHMB
Dietary Supplement: Placebo Gel Dosage
Dietary Supplement: Placebo
Registration Number
NCT01150526
Lead Sponsor
Metabolic Technologies Inc.
Brief Summary

The proposed study will test efficacy of HMB in free acid gel to decrease muscle damage, diminish inflammatory response, and improve muscle strength recovery following an acute exercise stress. HMB in a free acid gel or in CaHMB capsule form will be administered as either a single dose before a bout of acute exercise or in multiple doses (one before and three daily doses for the 4 days following the acute exercise). We hypothesize that HMB in free acid gel will result in less muscle damage, diminished inflammatory response, and improved muscle strength recovery than either a placebo or CaHMB treatment following a bout of acute eccentric exercise. Our endpoints will include measurements of: (1) markers for muscle damage (CPK and LDH); (2) indicators of inflammation (CRP, TNF-α, IL-6, IL-1ra and IL-18); and (3) muscle strength recovery and soreness.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Must live within 50 miles of Ames, Iowa
  • Free of cardiac, liver, pulmonary, and kidney disease
  • Free of chronic inflammatory disease including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and psoriasis
  • Free diabetes mellitus
  • Not classified as morbidly obese (BMI must be less than 40)
  • Free of cardiac, liver, pulmonary, and kidney disease
  • No other serious medical illness
  • Normal menstrual cycle and not pregnant or lactating
  • Able to consume supplements and perform required exercise testing
Exclusion Criteria
  • Live more than 50 miles from Ames, Iowa
  • Presence of cardiac, liver, pulmonary, and kidney disease
  • Presence of chronic inflammatory disease including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and psoriasis
  • Diabetes mellitus
  • Classified as morbidly obese (BMI is greater than 40)
  • No other serious medical illness
  • Abnormal menstrual cycle, pregnant or lactating
  • Not able to consume supplements and perform required exercise testing

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CaHMB Pre and PostPlacebo Gel DosageOral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
HMB Free Acid Gel PreHMB Free Acid GelOral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
HMB Free Acid Gel PrePlaceboOral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
HMB Free Acid Gel PrePlacebo Gel DosageOral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
HMB Free Acid Gel Pre and PostHMB Free Acid GelOral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
HMB Free Acid Gel Pre and PostPlaceboOral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
PlaceboPlaceboOral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
PlaceboPlacebo Gel DosageOral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
CaHMB PreCaHMBOral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
CaHMB PrePlaceboOral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
CaHMB PrePlacebo Gel DosageOral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
CaHMB Pre and PostCaHMBOral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
Primary Outcome Measures
NameTimeMethod
Decrease in muscle damage and inflammation4 days post eccentric exercise bout

Serum analysis for markers of muscle damage (CPK) and inflammation (IL-6, IL-18, IL1ra, TNF-a, CRP) will be measured at 24, 48, 72, and 96 h post exercise bout

Secondary Outcome Measures
NameTimeMethod
Improvement in strength recovery and decrease in soreness4 days post eccentric exercise bout

Muscle strength recovery and soreness will be measured at 24, 48, 72, and 96 h post exercise bout.

Trial Locations

Locations (1)

Iowa State University

🇺🇸

Ames, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath